Gracell Biotechnologies Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Wei Cao BM,
- Full Time Employees
- 314
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building 12, Block B Suzhou People's Republic of China 215123
- IPO Date
- Jan 8, 2021
- CIK
- 0001826492
- Website
- gracellbio.com
- Similar Companies
- Business
- Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company and wholly-owned subsidiary of AstraZeneca, develops innovative cell therapies for cancer and autoimmune diseases leveraging its proprietary FasTCAR and TruUCAR platforms; FasTCAR enables next-day manufacturing of younger, less exhausted autologous CAR-T cells, while TruUCAR supports off-the-shelf allogeneic CAR-T therapies from non-HLA-matched donors. The company's lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T in Phase 2 for multiple myeloma and Phase 1 for systemic lupus erythematosus and other hematologic malignancies; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T in Phase 1 for relapsed/refractory B-cell acute lymphoblastic leukemia; GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T in Phase 1 for T-cell acute lymphoblastic leukemia; GC007g, a donor-derived CD19-directed allogeneic CAR-T in Phase 1/2 for CD19-expressing malignancies; and GC502, a TruUCAR-enabled dual CD19- and CD7-directed allogeneic CAR-T in Phase 1 for B-cell malignancies. Its earlier-stage pipeline targets solid tumors such as ovarian and breast cancers, as well as hematologic indications including peripheral T-cell lymphoma. Founded in 2017 and headquartered in Suzhou, China, with operations in Shanghai and Hong Kong, Gracell primarily serves patients in the People's Republic of China through partnerships with key hospitals for investigator-initiated trials supporting global regulatory filings. In February 2024, AstraZeneca completed its $1.2 billion acquisition of Gracell, adding GC012F and other candidates to its oncology portfolio and providing $234 million in cash reserves to advance clinical development.
Gracell Biotechnologies Acquisition Completed
Gracell Biotechnologies Announces Shareholders' Approval of Merger Agreement
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Gracell Biotechnologies Inc. Sponsored ADR (GRCL) is a Great Momentum Stock: Should You Buy?
GRACELL BIOTECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Gracell Biotechnologies Inc. - GRCL
Yes Virginia, There Is a Santa Claus Rally
GRCL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Gracell Biotechnologies Inc. Is Fair to Shareholders
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases
Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases
Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Is a Great Choice for 'Trend' Investors, Here's Why
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023
Wall Street Analysts Believe Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Could Rally 127.82%: Here's is How to Trade
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
What Makes Gracell Biotechnologies Inc. Sponsored ADR (GRCL) a Strong Momentum Stock: Buy Now?
Does Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Have the Potential to Rally 120.94% as Wall Street Analysts Expect?
Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit
Gracell Biotechnologies Inc. (GRCL) Q3 2023 Earnings Call Transcript
Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update
Should You Buy Gracell Biotechnologies (GRCL) Ahead of Earnings?